<DOC>
	<DOC>NCT00386581</DOC>
	<brief_summary>The study is designed to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy (in the morning). It incorporates a 6-week acute treatment period and a 2-week discontinuation phase. The assessments in this study include a standard assessment of ADHD symptomatology using a Diagnostic and Statistical Manual of Mental Disorders, Fourth Editionâ„¢, investigator-administered rating scale.</brief_summary>
	<brief_title>Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria Subjects must have ADHD that meets the DSMIV criteria Aged 6 to 16 years. Subjects must not have taken any medication used to treat ADHD. Laboratory results must show no significant abnormalities Baseline ECG results must not show an abnormality Subjects must be able to swallow capsules. Subjects must be of normal intelligence. Exclusion Criteria Weigh less than 20 kg or more than 60 kg at study entry. Subjects who, after an adequate trial with methylphenidate or amphetamine experience some benefit in ADHD signs and symptoms are excluded from participating. Have a history of Bipolar I or II disorder, psychosis, or PDD. Meet DSMIV criteria for an anxiety disorder. Have a history of any seizure disorder. Patients at serious suicidal risk. Patients with narrow angle glaucoma Subjects who have a history of severe allergies . Have a history of alcohol or drug abuse within the past 3 months Screen positive for drugs of abuse not prescribed by a physician. Have cardiovascular disease and an increased heart rate and blood pressure. Have a medical condition that would increase sympathetic nervous system activity markedly or who are taking a medication on a daily basis. Have severe gastrointestinal narrowing Are during the study time likely to need psychotropic medications. Are likely to begin a structured psychotherapy aimed at ADHD symptoms. Have used a monoamine oxidase inhibitor (MAOI) during the 2 weeks Female subjects who are pregnant or who are breastfeeding. Are investigative site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. Are, in the opinion of the investigator, unsuitable in any other way to participate in this study. Are employed by Lilly.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>